UNLABELLED: One of the mechanisms for multidrug resistance (MDR) of tumors is an overexpression of the P-glycoprotein (P-gp). The cytostatic agent daunorubicin and the modulator verapamil were labeled with 11C to probe P-gp with PET. METHODS: Carbon-11-daunorubicin was prepared from 11CCH2N2 with an aldehyde precursor, followed by hydrolysis. Carbon-11-verapamil was synthesized by 11C-methylation. Both tracers were evaluated by investigating pharmacokinetics in rats and in vitro cell kinetics using human ovarian carcinoma cells. RESULTS: Amounts of 111 MBq 11C-daunorubicin were prepared. Biodistribution studies of 11C-daunorubicin in male Wistar rats showed dose-dependent pharmacokinetics, whereas with 11C-verapamil the pharmacokinetics were dose independent. In in vitro experiments with cells, the ratio of accumulation of 11C-daunorubicin in drug sensitive/resistant cell lines was 16. Addition of verapamil resulted in increased accumulation of 11C-daunorubicin in the resistant cell line. The ratios of 11C-verapamil accumulation in drug-sensitive versus the MDR counterpart were 4-5. CONCLUSION: Carbon-11-daunorubicin and 11C-verapamil both have potential for in vivo probing of P-glycoprotein with PET.
UNLABELLED: One of the mechanisms for multidrug resistance (MDR) of tumors is an overexpression of the P-glycoprotein (P-gp). The cytostatic agent daunorubicin and the modulator verapamil were labeled with 11C to probe P-gp with PET. METHODS:Carbon-11-daunorubicin was prepared from 11CCH2N2 with an aldehyde precursor, followed by hydrolysis. Carbon-11-verapamil was synthesized by 11C-methylation. Both tracers were evaluated by investigating pharmacokinetics in rats and in vitro cell kinetics using humanovarian carcinoma cells. RESULTS: Amounts of 111 MBq 11C-daunorubicin were prepared. Biodistribution studies of 11C-daunorubicin in male Wistar rats showed dose-dependent pharmacokinetics, whereas with 11C-verapamil the pharmacokinetics were dose independent. In in vitro experiments with cells, the ratio of accumulation of 11C-daunorubicin in drug sensitive/resistant cell lines was 16. Addition of verapamil resulted in increased accumulation of 11C-daunorubicin in the resistant cell line. The ratios of 11C-verapamil accumulation in drug-sensitive versus the MDR counterpart were 4-5. CONCLUSION:Carbon-11-daunorubicin and 11C-verapamil both have potential for in vivo probing of P-glycoprotein with PET.
Authors: Janet F Eary; Jeanne M Link; Mark Muzi; Ernest U Conrad; David A Mankoff; Jedediah K White; Kenneth A Krohn Journal: J Nucl Med Date: 2011-03-18 Impact factor: 10.057
Authors: Philip H Elsinga; N Harry Hendrikse; Joost Bart; Aren van Waarde; Willem Vaalburg Journal: Mol Imaging Biol Date: 2005 Jan-Feb Impact factor: 3.488
Authors: Neva Lazarova; Sami S Zoghbi; Jinsoo Hong; Nicholas Seneca; Ed Tuan; Robert L Gladding; Jeih-San Liow; Andrew Taku; Robert B Innis; Victor W Pike Journal: J Med Chem Date: 2008-09-11 Impact factor: 7.446
Authors: Fijs W B van Leeuwen; Tessa Buckle; Ariena Kersbergen; Sven Rottenberg; Kenneth G A Gilhuijs Journal: Eur J Nucl Med Mol Imaging Date: 2008-12-18 Impact factor: 9.236
Authors: Jens P Bankstahl; Claudia Kuntner; Aiman Abrahim; Rudolf Karch; Johann Stanek; Thomas Wanek; Wolfgang Wadsak; Kurt Kletter; Markus Müller; Wolfgang Löscher; Oliver Langer Journal: J Nucl Med Date: 2008-07-16 Impact factor: 10.057
Authors: Aiman Abrahim; Gert Luurtsema; Martin Bauer; Rudolf Karch; Mark Lubberink; Ekaterina Pataraia; Christian Joukhadar; Kurt Kletter; Adriaan A Lammertsma; Christoph Baumgartner; Markus Müller; Oliver Langer Journal: Eur J Nucl Med Mol Imaging Date: 2007-09-11 Impact factor: 9.236